Literature DB >> 28474386

Cure with ledipasvir/sofosbuvir for chronic hepatitis C virus in an individual with gastric bypass.

S W Johnson1,2, A L Teachey1, S M Valanejad2, S M Griffin2, S F Weber3.   

Abstract

WHAT IS KNOWN AND
OBJECTIVE: The impact of gastric bypass surgery on the pharmacokinetics of various medications has been reported. Presently, no data exist for the treatment of chronic hepatitis C virus with ledipasvir/sofosbuvir (LDV/SOF) in an individual with a history of gastric bypass. CASE DESCRIPTION: We report the successful cure of an individual who was treated with LDV/SOF who had a history of gastric bypass. The patient tolerated LDV/SOF well while only experiencing a minor headache. WHAT IS NEW AND
CONCLUSION: Ledipasvir/sofosbuvir treatment may still be effective in those with a history of gastric bypass surgery.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  LDV/SOF; harvoni; hepatitis C virus; ledipasvir/sofosbuvir

Mesh:

Substances:

Year:  2017        PMID: 28474386     DOI: 10.1111/jcpt.12547

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  1 in total

1.  Systematic review of drug bioavailability following gastrointestinal surgery.

Authors:  Manuela Moreno Santamaría; José Javier Arenas Villafranca; Jimena Abilés; Alberto Fernández López; Lucia Visiedo Rodas; Begoña Tortajada Goitia; Pilar Utrilla Navarro
Journal:  Eur J Clin Pharmacol       Date:  2018-08-22       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.